Major Facilitator Superfamily transporters: recent advances in structure, mechanism, and therapeutic targeting

lmmol AI Research Collective · Published 2026-06-25 · lmmol:review:PF07690

🧪 lmctl-orchestrated review — written by an orchestrated team of AI agents, grounded in 1,818 papers from lmmol's literature graph. Citations link to their source on PubMed.

1. Overview

The Major Facilitator Superfamily (MFS, Pfam MFS_1, PF07690) is the largest group of secondary membrane transporters in the cell ^[1]. Foundational structural work on the bacterial glycerol-3-phosphate transporter GlpT established the canonical MFS architecture, in which the amino- and carboxy-terminal halves of the protein form a pseudo two-fold symmetric pair of six-transmembrane bundles enclosing a central substrate-translocation pore ^[1]. From this structure emerged the single-binding-site, alternating-access model in which substrate transport proceeds through a rocker-switch movement of the two halves ^[1]. The MFS in humans spans many physiologically central solute carrier (SLC) families, including the monocarboxylate transporters of the SLC16 family that move lactate, pyruvate, and ketone bodies across membranes in a proton-linked manner ^[2], and the substrate breadth extends to organic anions, drugs, and neurotransmitters. The past several years have shifted the field from sequence-and-physiology characterization toward high-resolution cryo-EM and crystallographic snapshots that capture distinct conformational states and drug-bound complexes.

2. Key proteins

The recency-weighted substrate centers on several heavily studied human MFS members. The SLC16 monocarboxylate transporters MCT1, MCT4, and MCT8 are prominent: MCT1 and MCT4 are proton-linked lactate transporters that require the ancillary protein CD147/Basigin for plasma-membrane expression ^[3], while MCT8 (SLC16A2) is a specific thyroid hormone transporter ^[4]. Other key proteins include the proton-coupled folate transporter PCFT/HCP1 ^[5], the renal urate anion exchanger URAT1 (SLC22A12) ^[6], the vesicular glutamate transporters VGLUT1 and VGLUT2 ^[7][8], the synaptic vesicle glycoprotein SV2A ^[9], the vesicular amine transporter ^[10], and the choline transporter FLVCR1 ^[11]. SLC16A11 has emerged as a type 2 diabetes risk gene ^[12], and SLC46A2 and SLC46A3 act as importers and lysosomal transporters relevant to immunotherapy and antibody-drug conjugates ^[13][14].

3. Recent advances

The defining recent advance is the arrival of cryo-EM structures of human MFS transporters bound to substrates and drugs. Five cryo-EM structures of human MCT1 at 3.0-3.3 Angstrom, solved in complex with the single-transmembrane chaperone Basigin-2, captured the transporter bound to its substrate lactate and to anti-cancer inhibitors, revealing both outward-open states (with lactate or the inhibitors BAY-8002 and AZD3965) and inward-open states (with the inhibitor 7ACC2, or upon neutralization of the proton-coupling residue Asp309) ^[15]. These structures elucidated the substrate-binding and transport mechanism and explained subtype-specific inhibitor sensitivities of MCT1 versus MCT4 ^[15]. In parallel, the cryo-EM structure of rat VGLUT2 at 3.8 Angstrom provided the first structural framework for vesicular glutamate transport and proposed structure-based mechanisms for substrate recognition and allosteric activation by low pH and chloride, identifying a chloride permeation pathway intersecting the glutamate binding site ^[16].

Beyond structures, transporter physiology has been substantially refined. MCT4 was re-characterized as a high-affinity lactate transporter (K_m in the low millimolar range rather than tens of millimolar), correcting earlier estimates biased by confounding pH-regulatory effects, and shown to enable lactate export specifically in high-lactate microenvironments ^[17]. MCT1 was found to mediate pH-gated secretion of succinate from exercising muscle, where transient protonation of succinate to its monocarboxylic form renders it an MCT1 substrate that then signals through SUCNR1 to coordinate muscle remodeling ^[18]. Integrative genetic analyses identified FLVCR1 as a major plasma-membrane choline transporter in mammals, with loss impairing choline metabolism and causing embryonic lethality partially rescued by choline supplementation ^[11]. Genome-wide analyses also identified SLC17A4 as a novel thyroid hormone transporter ^[19].

4. Structural & mechanistic insights

The structural data converge on the alternating-access framework first defined for GlpT ^[1]. For the SLC16 family, crystal structures of a bacterial homologue in the outward-open conformation, captured with two different bound ligands at 2.54 and 2.69 Angstrom, provided detailed insights into ligand binding and L-lactate transport ^[20]. The human MCT1 cryo-EM series extended this by capturing both outward- and inward-open conformations, directly visualizing the proton-coupling residue Asp309 whose neutralization shifts the conformational equilibrium ^[15]. Mechanistic work on vesicular transport showed that VGLUT1 functions as a glutamate/proton exchanger with an associated channel-like chloride conductance, driven by both the chloride gradient and the proton-motive force from the vacuolar H+-ATPase ^[21], consistent with the chloride-coupled activation seen structurally in VGLUT2 ^[16]. A recurring theme is the dependence of MFS transporters on accessory partners: CD147/Basigin is required for cell-surface expression of MCT1 and MCT4 ^[3], and disruption of the SLC16A11-Basigin interaction reduces transporter surface localization in a disease context ^[12].

5. Disease & therapeutic relevance

MFS transporters are directly implicated in human disease and are active drug targets. MCT1 inhibitors including AZD3965, BAY-8002, and 7ACC2 are anti-cancer candidates exploiting the elevated expression of MCTs in tumors, and the MCT1 structures provide a framework for structure-guided drug discovery ^[15]. MCT8 mutations cause a syndrome of severe X-linked psychomotor retardation with abnormal thyroid hormone levels ^[22][23], and patient-derived iPSC models implicated the blood-brain barrier as a key site of MCT8-dependent thyroid hormone entry, suggesting that delivering active hormone across the diseased barrier is a viable therapeutic strategy ^[24]. URAT1 is the renal urate exchanger targeted by uricosuric agents, and its loss underlies idiopathic renal hypouricaemia ^[6]. PCFT/HCP1 loss-of-function underlies hereditary folate malabsorption ^[5]. SLC16A11 variants raise type 2 diabetes risk by reducing transporter expression and surface localization, suggesting that increasing its function could be beneficial ^[12]. SV2A is the binding site for the antiepileptic levetiracetam ^[9] and the receptor for botulinum neurotoxin A ^[25], and the vesicular amine transporter modulates susceptibility to the Parkinsonian toxin MPP+ ^[10]. In oncology delivery, SLC46A3 predicts sensitivity to noncleavable-linker antibody-drug conjugates ^[14], and SLC46A2 imports cGAMP in macrophages relevant to STING-pathway immunotherapy ^[13].

6. Open questions & gaps

Structural coverage remains uneven. High-resolution human structures exist for MCT1 ^[15] and VGLUT2 ^[16], but for many key human MFS members in this substrate, including PCFT, URAT1, MCT8, FLVCR1, and the SLC46 family, the substrate provides physiological and genetic characterization without accompanying high-resolution structures, so the molecular basis of their substrate selectivity and any inhibitor binding is thinly represented here. The full transport cycle is incompletely captured even where structures exist, since the MCT1 series visualizes outward- and inward-open states but the intermediate occluded transitions are not described in the substrate ^[15]. Mechanistic disagreements persist in kinetics, as illustrated by the substantial revision of MCT4 substrate affinities once pH artifacts were controlled ^[17], implying that other reported affinities may warrant re-examination. For MCT8 disease, the relative contributions of neuronal versus blood-brain-barrier transport remain an open therapeutic question ^[24]. Finally, the substrate is sparse on the large bacterial and fungal drug-efflux DHA branch of the MFS, represented mainly by the EmrAB pumps in colistin resistance ^[26] and the engineered CexA citrate exporter ^[27], so mechanistic generalization of the recent human-focused structural insights to clinically important multidrug-efflux MFS pumps is not directly supported by the available evidence.